Merck Serono Launches R&D Facility in Beijing

The R&D facility in Beijing will have its main focus on individualized treatments for cancer and other diseases.

Merck Serono launched operations last week at its R&D facility in Beijing. The main focus of the research facility will be individualized treatments for cancer and other diseases.

The facility has opened nearly two years after the company announced it would pour $225 million into the operation and employ hundreds of workers. Complementing its research hubs in the U.S., Germany and Switzerland, the Beijing lab will focus on drugs for cancer, neurodegenerative disorders, autoimmune and inflammatory diseases that are tailored for specific patients based on their genetics and other biological traits, according to the article.

While making research investments in the country, Merck Serono is keeping a close eye on the growing pharmaceutical market in China. Wayne Paterson, the company's executi